Gå ubegrenset med Magzter GOLD

Gå ubegrenset med Magzter GOLD

Få ubegrenset tilgang til over 9000 magasiner, aviser og premiumhistorier for bare

$149.99
 
$74.99/År

Prøve GULL - Gratis

Green manufacturing in pharma: Sustainable oligonucleotide production on an industrial scale

Express Pharma

|

November 2024

Philipp Markolin, Scientific Marketing Manager at peptide and oligonucleotide manufacturers Bachem, shares their expertise on sustainable production methods in the pharma industry

- Philipp Markolin

Green manufacturing in pharma: Sustainable oligonucleotide production on an industrial scale

Oligonucleotides are at the forefront of modern medicine, and have emerged as powerful tools in treating diseases in recent years. Oligonucleotides - short DNA or RNA molecules that host a range of applications in genetic testing, research, and forensics have seen a marked growth in significance as therapeutics. As their clinical application widens, methods of production must be robust to ensure demand is met.

Demand for oligonucleotides in medicines is steadily increasing, with a pressing need for an eco-friendly manufacturing process which satisfies green manufacturing standards without compromising yield or process efficiency. Thus, the responsibility lies with manufacturers to ensure end users receive their medications, while striving for sustainable production methods.

The importance of sustainable oligonucleotide synthesis

The need for sustainability in oligonucleotide manufacturing is increasing rapidly, driven by the growing use of these therapeutics to treat a diverse variety of conditions. With the oligonucleotide and peptide therapeutics market projected to grow at an annual rate of 17.5 per cent through 2030, the industry faces significant challenges such as high production costs, waste, and energy-intensive processes.

With new oligonucleotide-based drugs being approved for development on a regular basis, the need for affordable and eco-friendly methods of production becomes more ur- recycling, process efficiency, gent.

The benefits of green manufacturing are twofold: sustainable practices help reduce environmental impact, but also address economic and regulatory demands, leading to improved efficiency and accountability.

What steps can pharma manufacturers take to improve sustainability?

FLERE HISTORIER FRA Express Pharma

Express Pharma

Express Pharma

Flexotherm Heating Tapes & Cords

Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling

time to read

1 mins

October 2025

Express Pharma

Express Pharma

DRIVING INDIA'S INNOVATION EDGE

Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership

time to read

16 mins

October 2025

Express Pharma

Express Pharma

Al compass: Transforming pharma commercialisation

As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations

time to read

7 mins

October 2025

Express Pharma

Express Pharma

PRIME NEO: New age doors from Gandhi Automation

Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.

time to read

1 mins

October 2025

Express Pharma

Express Pharma

Unani Medicine: At crossroads of tradition and modernity

Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana

time to read

7 mins

October 2025

Express Pharma

Express Pharma

Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand

The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.

time to read

1 min

October 2025

Express Pharma

Express Pharma

Sustainable packaging with Romaco and Liveo Research

Recycable blister packs

time to read

3 mins

October 2025

Express Pharma

Express Pharma

With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here

As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.

time to read

3 mins

October 2025

Express Pharma

Express Pharma

Cell therapy's next chapter: Industry embraces in-vivo innovation

Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases

time to read

4 mins

October 2025

Express Pharma

Express Pharma

Research misconduct ...can delay meaningful and reliable discoveries

Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions

time to read

6 mins

October 2025

Listen

Translate

Share

-
+

Change font size